THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ONCommon Stock Purchase Warrant • February 3rd, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
BrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) on February 17, 2015, 500,000 shares of Common Stock, $0.00005 par value per share, of the Company, at a purchase price of $0.001 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively.
THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUED UPON ITS EXERCISE ARE SUBJECT TO THE RESTRICTIONS ONCommon Stock Purchase Warrant • February 3rd, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
BrainStorm Cell Therapeutics, Inc., a Delaware corporation (the “Company”), for value received, hereby certifies that Hadasit Medical Research Services and Development Ltd., or its registered assigns (the “Registered Holder”), is entitled, subject to the terms and conditions set forth below, to purchase from the Company, at any time or from time to time on or after the date of issuance and on or before 5:00 p.m. (New York time) on April 13, 2020 (the “Expiration Date”), 33,334 shares of Common Stock, $0.00005 par value per share, of the Company, at a purchase price of $0.00005 per share. The shares purchasable upon exercise of this Warrant, and the purchase price per share, each as adjusted from time to time pursuant to the provisions of this Warrant, are hereinafter referred to as the “Warrant Shares” and the “Purchase Price,” respectively.
FIRST AMENDMENT TO AGREEMENTAmendment to Agreement • February 3rd, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances)
THIS FIRST AMENDMENT TO AGREEMENT (“Amendment”) is made as of December 31, 2011 by and among Prof. Avi Israeli, Hadasit Medical Research Services and Development Ltd. and BrainStorm Cell Therapeutics Inc. (together, the “Parties”).
ASSIGNMENT AGREEMENTAssignment Agreement • February 3rd, 2012 • Brainstorm Cell Therapeutics Inc • Biological products, (no disgnostic substances)
THIS ASSIGNMENT AGREEMENT (the “Agreement”) is made and entered into as of, December 20, 2011, with effective date of January 1, 2007 (the “Effective Date”), by and between BrainStorm Cell Therapeutics Inc., a company incorporated under the laws of the State of Delaware, having its corporate headquarters at East 59th Street, New York, NY 10019 USA (the “Assignor”), and Brainstorm Cell Therapeutics Ltd., a limited liability company incorporated under the laws of the State of Israel, having a place of business at 12 Bazel Street, Street, Petach Tikva, Israel 49170 (the “Assignee”).
